The American Society of Hematology Education Roadmap

American Society of Hematology pic
American Society of Hematology

A board-certified oncologist with more than 20 years of experience, Matthew Taub, MD, practices at Optimum Oncology Hematology Associates in Pembroke Pines, Florida. An active participant in the professional community, Dr. Matthew Taub maintains membership in the American Society of Hematology (ASH).

The leading provider of continuing education to hematologists, ASH recently developed an “Education Roadmap” that seeks to expand the society’s professional development offerings and address the skill gaps and educational needs of its members. ASH is working on enhancing its content in six areas: precision medicine, acute myeloid leukemia, sickle cell disease, immune therapies, systems-based hematology, and hemostasis and thrombosis.

In addition to in-person conferences and training, ASH offers an eLearning platform called ASH Academy with up-to-date clinical information and practice tools. By completing ASH Academy courses and evaluations, members can earn continuing medical education credits to maintain certifications. The ASH On Demand service also makes previous educational meetings and webinars available to members for on-demand viewing.

ASCO Highlights Recent Cancer Treatment Advances

Matthew Taub
Matthew Taub

Dr. Matthew Taub, a board-certified physician specializing in internal medicine, hematology, and oncology, possesses more than 20 years of clinical experience. In addition to his work on several medical committees, Dr. Matthew Taub holds membership in the American Society of Clinical Oncology (ASCO).

For over a decade, ASCO has released Clinical Cancer Advances, an annual report detailing the year’s most significant advances in cancer treatment. The 2018 release brings focus to several Food and Drug Administration-approved therapies for their impact in the fight against cancer.

In 2017, the FDA approved pembrolizumab for use in patients with certain types of metastatic tumors. The immunotherapy drug is first in a line of tissue-agnostic therapies, treatments that work based on a tumor’s biomarkers, to be approved.

The report also chronicles improvements in targeted therapies for lung, breast, and bladder cancers and reviews the promising effects of radiotherapy and tumor-treating fields on aggressive forms of brain cancer.

Three Factors That Increase the Risk of Anemia



Pembroke Pines, Florida-based physician Dr. Matthew Taub has more than two decades of experience treating blood-related disorders and cancers at Optimum Oncology Hematology Associates. At the clinic, Dr. Matthew Taub is part of a multidisciplinary staff that addresses common blood disorders such as anemia.

Anemia is a red blood cell disorder that affects more than 3 million Americans. In addition to a low hemoglobin count, anemia causes fatigue, headaches, and irregular heartbeats. The following risk factors are highly associated with anemia:

Limited Diet: Anemia can be triggered by a diet lacking in vitamin B12, iron, and folate. For this reason, people who eat restricted diets, including vegan and vegetarian, are especially susceptible.

Age: The likelihood of developing anemia due to iron deficiency increases after the age of 65. Additionally, women may experience low iron levels during pregnancy and childbirth, making anemia more common for women around childbearing age.

Associated Diagnosis: Anemia is also associated with other chronic illnesses, including cancer as well as diseases of the thyroid, liver, and kidneys. Autoimmune diseases such as rheumatoid arthritis have also been linked to a higher likelihood of anemia.